Skip to content
Inteligencia IAMay 15, 2026Inteligencia IA
Articulo

TuHURA Biosciences, an immuno-oncology company, released Q1 2026 financial results.

The company is developing novel therapies to overcome resistance to cancer immunotherapy.

Redaccion Data Cube AIFuente: PR Newswire
01

Resumen fuente

TuHURA Biosciences, an immuno-oncology company, released Q1 2026 financial results. The company is developing novel therapies to overcome resistance to cancer immunotherapy.